COMPANY OVERVIEW

NanOlogy, LLC is a clinical stage development company formed between DFB Pharmaceuticals, CritiTech, and US Biotest to advance our patented nanoparticle production technology platform for the treatment of cancer and other serious illnesses. Their technology platform reduces unprocessed paclitaxel and docetaxel API crystals by up to 400 times into patented, stable, naked nanoparticles with tremendous surface area and unique geometry.

---

LOCATION

Fort Worth, TX, USA

---

THERAPEUTIC AREAS

Oncology

---

WEBSITE

https://nanology.us/

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Jun 7, 2023

NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs

Mar 7, 2023

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

Dec 20, 2022

NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts

Nov 11, 2022

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer

Oct 3, 2022

CORRECTING and REPLACING NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX

For More Press Releases

---